Organon & Co. (NYSE: OGN) AI-Powered Stock Analysis
See how Organon & Co. scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.
OGN●NYSE
HealthcareDrug Manufacturers - General
$13.73
$0.005(0.04%)
U.S. Market opens in 65h 28m
Organon & Co. (NYSE: OGN) AI-Powered Stock Analysis
See how Organon & Co. scores across key metrics like financial growth, valuation, and market position on the NYSE, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerOrganon & Co. (NYSE: OGN) Stock Overall Grade
Organon & Co.'s grade for its NYSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Organon & Co.'s overall NYSE stock rating.
Forecast
C+Score
56/100Financial Growth
CScore
40/100Fundamental Growth
AScore
83/100Key Ratios
AScore
81/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Organon & Co. (NYSE: OGN) AI-Powered Stock Analysis
On the NYSE, OGN demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (83/100, A) highlight its stability, while Key Ratios (81/100, A) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the NYSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(NYSE: OGN) Component Analysis Explained
Understand the key factors behind each Organon & Co. (NYSE: OGN) stock grade, including financials, comparisons, and forecasts.